Scancell shares healthy following patent approval award in Japan

Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.

Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.

The same patent has already been approved in the US, Europe and Australia.

Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This is a further important step in the development and commercialisation of the ImmunoBody platform and provides further evidence to support the novelty of Scancell's ImmunoBody technology in another key pharmaceutical market.

"Scancell will continue building its growing portfolio of intellectual property in parralel with driving the clinical trial programme on SCIBI forward during 2013."

SCIBI is Scancell's first cancer vaccine which is currently being developed for the treatment of melanoma.

Scancell's share price was up 6.37% to 41.75p at 11:01 on Wednesday.

MF

Recommended

Three sustainable stocks that are doing well by doing good
Share tips

Three sustainable stocks that are doing well by doing good

Professional investor Peter Michaelis of the Liontrust Sustainable Investment Team picks three stocks to buy that are helping to create a cleaner, saf…
26 Jul 2021
Share tips of the week – 23 July
Share tips

Share tips of the week – 23 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
23 Jul 2021
Will Zoom’s $15bn purchase help it expand?
Tech stocks

Will Zoom’s $15bn purchase help it expand?

The videoconferencing platform became a household name during the pandemic, but it now needs new sources of growth. Alex Rankine reports
23 Jul 2021
Philip Morris goes “beyond nicotine”
Stocks and shares

Philip Morris goes “beyond nicotine”

US tobacco giant Philip Morris International has agreed to pay £1bn for British inhaler specialist Vectura.
23 Jul 2021

Most Popular

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
Three companies that are reaping the rewards of investment
Share tips

Three companies that are reaping the rewards of investment

Professional investor Edward Wielechowski of the Odyssean Investment Trust highlights three stocks that have have invested well – and are able to deal…
19 Jul 2021